We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 7 for:    Recruiting Studies | dupuytren

Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD)

This study is currently recruiting participants.
Verified June 2017 by University of Oxford
Sponsor:
ClinicalTrials.gov Identifier:
NCT03180957
First Posted: June 8, 2017
Last Update Posted: June 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Department of Health, United Kingdom
Wellcome Trust
180 Therapeutics LP
Information provided by (Responsible Party):
University of Oxford
  Purpose

Dupuytren's disease is a very common condition, affecting 4% of the general UK and US population. It causes the fingers to curl irreversibly into the palm and can be extremely disabling. The disease usually starts as a small firm lump (nodule) in the palm, and in about 40% of patients advances to form cords that pull the fingers into the palm. There is no approved treatment for the early stage of disease. Once patients have established deformities, the diseased tissue can removed by surgery or cut using less invasive techniques such as a needle or an enzyme. However, recovery following surgery usually takes several months and recurrence rates with the less invasive techniques are high.

The investigators have unravelled the cellular process that initiates and maintains the disease progress and identified tumour necrosis factor (TNF) as a new target for treatment. Based on these findings the investigators plan to test the effects of adalimumab, an anti-TNF drug which currently approved for use in patients with rheumatoid arthritis and other inflammatory conditions. The aim of the study is to find out whether treatment by injection with adalimumab directly into the diseased tissue will control the advance of early Dupuytren's disease better than a placebo injection with normal saline.

The investigators will first carry out a small trial in up to 40 patients with established disease to determine the best dose that reduces the activity of the cells responsible for the disorder (Dose Response study). In this part patients who will be having surgery to remove their diseased tissue will receive a single injection of adalimumab into the nodule in their hand about 2 weeks before surgery. The tissue that is then removed during surgery will be analysed in the investigator's laboratories to determine the effect of the drug on the tissue. Patients will be followed for 12 weeks after surgery.

In the second part of the study the investigators will assess whether the optimal dose of the drug prevents early disease advancing in 138 patients (Early Disease study). Patients who take part in the second part of the study will receive a total of 4 injections of adalimumab into the nodule in their hand at three monthly intervals. They will then be checked at 6 months after the last injection. In additional to assessing the effect of the injections on the nodule and hand function, information will also be collected to assess the cost effectiveness of the treatment.


Condition Intervention Phase
Dupuytren's Disease Drug: Adalimumab Drug: Saline Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-centre, Double Blind, Randomised, Placebo-controlled, Parallel Group, Phase II Trial to Determine the Efficacy of Intra-nodular Injection of Anti-TNF to Control Disease Progression in Early Dupuytren's Disease, With a Dose Response.

Resource links provided by NLM:


Further study details as provided by University of Oxford:

Primary Outcome Measures:
  • Dose Response: expression of mRNA for α-SMA [ Time Frame: Analysis of tissue removed at 12-18 days post-treatment ]
  • Early Disease: change in nodule hardness from baseline at 12 weeks [ Time Frame: 12 weeks ]
    Tonometry


Secondary Outcome Measures:
  • Dose Response: expression of mRNA for COL-1A1 and COL-3A1 [ Time Frame: Analysis of tissue removed at 12-18 days post-treatment ]
  • Dose Response: Levels of α-SMA protein [ Time Frame: Analysis of tissue removed at 12-18 days post-treatment ]
  • Dose Response: Nodule hardness [ Time Frame: 2 weeks post treatment ]
    Tonometry

  • Dose Response & Early Disease: Change in nodule size and vascularity from baseline [ Time Frame: 2 weeks post treatment (dose response) / 18 months (early disease) ]
    Pixel analysis of ultrasound imaging

  • Dose Response and Early Disease: participant injection experience [ Time Frame: Baseline (Dose response) / 12 months (early disease) ]
    Numeric rating scale of pain

  • Dose Response & Early Disease: Adverse event assessment [ Time Frame: 2 weeks (dose response) / 12 months (early disease) ]
    Assessment of the injection site for pre-specified Adverse Events; surgery site assessment (Dose response only): wound assessment criteria, Centres for Disease Control and Prevention.

  • Early Disease: range of motion of the affected digit [ Time Frame: 18 months ]
    Goniometer reading

  • Early Disease: Grip strength [ Time Frame: 18 months ]
    Jamar meter

  • Early Disease: patient reported outcomes [ Time Frame: 18 months ]
    Michigan hand Outcomes Questionnaire

  • Early Disease: patient reported outcomes [ Time Frame: 18 months ]
    Participant identified activity most restricted by DD scored on a scale of 1-10

  • Early Disease: progression to surgery of the digit being assessed [ Time Frame: 18 months ]

Other Outcome Measures:
  • Dose Response & Early Disease: Circulating levels of adalimumab in the blood [ Time Frame: 2 weeks (dose response) / 12 months (early disease) ]
  • Dose Response & Early Disease: Circulating levels of antibodies to adalimumab in the blood [ Time Frame: 2 weeks (dose response) / 12 months (early disease) ]
  • Dose Response: Acceptability of the injection and return to paid work [ Time Frame: 12 weeks post-surgery ]
    Patient-completed questionnaire: numeric rating scale

  • Early Disease: Cost effectiveness [ Time Frame: 18 months ]
    EQ-5D-5L data


Estimated Enrollment: 178
Actual Study Start Date: March 2, 2016
Estimated Study Completion Date: July 2018
Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Anti-TNF
adalimumab
Drug: Adalimumab
Other Name: Humira
Placebo Comparator: Placebo
saline
Drug: Saline

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant is willing and able to give informed consent for participation in the study.
  • Male or Female, aged 18 years or above.
  • For Part 1: Diagnosed with DD affecting the fingers resulting in flexion deformities of ≥30° at the metacarpophalangeal joint and or the proximal interphalangeal joint with impaired hand function and awaiting surgery. Or for Part 2: Participants with early disease nodules who have shown or reported progression of the disease in the previous 6 months with flexion deformities of ≤30° at the metacarpophalangeal and/or at the proximal interphalangeal joint, i.e. total flexion deformity of up to 60°.
  • The DD nodule to be treated must be distinct and identifiable.
  • Female participants of child bearing potential, and male participants whose partner is of child bearing potential, must be willing to ensure that they or their partner use effective contraception throughout the treatment period and for 5 months following the last research injection. Acceptable methods of contraception include: a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods), injectables, the combined oral contraceptive pill (at a stable dose for at least 3 months before entering the study), an intrauterine device, vasectomised partner, or true sexual abstinence (when this is in line with the preferred and usual lifestyle of the participant).
  • Participant results from safety screening tests within normal ranges within 8 weeks of enrolment, with the exception that an earlier clear chest x-ray result may be used where this is in accordance with the time frames of local standard procedures for anti-TNF screening.
  • Able (in the Investigators opinion) and willing to comply with all study requirements.
  • Willing to allow his or her general practitioner to be notified of participation in the study.
  • Sufficient language fluency to ensure informed consent is obtained and to complete the questionnaires pertaining to hand function.

Exclusion Criteria:

  • For Part 1: Participant has previously had fasciectomy, dermofasciectomy, needle fasciotomy, collagenase injection, steroid injection or radiotherapy to treat Dupuytren's disease in the digit concerned. Or for Part 2: Participant has previously had fasciectomy, dermofasciectomy, needle fasciotomy, collagenase injection, steroid injection or radiotherapy to treat Dupuytren's disease in the hand concerned.
  • Female participant who is pregnant, lactating or planning pregnancy during the course of the study and for 5 months following last injection.
  • Male participant who is planning a pregnancy during the course of the study and for 5 months following last injection.
  • Significant renal or hepatic impairment.
  • For Part 1: Scheduled elective surgery or other procedures requiring general anaesthesia during the study other than the scheduled Dupuytren's surgery. Or for Part 2: Scheduled elective surgery or other procedures requiring general anaesthesia during the study
  • Participant who has ever been diagnosed with cancer, is terminally ill or is inappropriate for placebo medication
  • Systemic inflammatory disorder such as rheumatoid arthritis (RA) or inflammatory bowel disease.
  • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
  • Participated in another research study involving an investigational medicinal product in the past 12 weeks.
  • Known allergy to any anti-TNF agent.
  • Have HIV or hepatitis B or C.
  • Known to have an infection or history of repeated infections.
  • History of Tuberculosis (TB).
  • Have Multiple Sclerosis (MS) or other demyelinating disease.
  • History of local injection site reactions.
  • Needle phobia.
  • Have moderate or severe heart failure.
  • Part 1: Being treated with coumarin anticoagulants, such as warfarin.
  • Have known lung fibrosis (thickening of lung tissue).
  • Being treated with concomitant biologic DMARDS.
  • Have received a live vaccine within the previous 4 weeks. Participants may receive concurrent vaccinations but must avoid the use of live vaccines for 12 weeks after their last injection.
  • Have received parenteral steroid within the previous 6 weeks.
  • Participants with epilepsy or a known allergy to tetracaine may take part in the study but will not receive Ametop gel as a local anaesthetic. Participants with a known allergy to lidocaine or prilocaine will not receive lidocaine/prilocaine cream/EMLA cream as a local anaesthetic.
  • Part 2: Participants at risk of Hepatitis B infection.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03180957


Contacts
Contact: RIDD Trial Manager +44 (0)0165 612610 ridd@kennedy.ox.ac.uk

Locations
United Kingdom
Queen Victoria Hospital NHS Foundation Trust Completed
East Grinstead, United Kingdom, RH19 3DZ
NHS Lothian Active, not recruiting
Edinburgh, United Kingdom, EH1 3EG
Oxford University Hospitals NHS Foundation Trust Recruiting
Oxford, United Kingdom, OX3 9DU
Contact: RIDD Trial Manager    01865 612610    ridd@kennedy.ox.ac.uk   
Sponsors and Collaborators
University of Oxford
Department of Health, United Kingdom
Wellcome Trust
180 Therapeutics LP
Investigators
Principal Investigator: Jagdeep Nanchahal, PhD FRCS University of Oxford
  More Information

Additional Information:
Responsible Party: University of Oxford
ClinicalTrials.gov Identifier: NCT03180957     History of Changes
Other Study ID Numbers: 11069
HICF-R8-433 ( Other Grant/Funding Number: Health Innovation Challenge Fund )
2015-001780-40 ( EudraCT Number )
ISRCTN27786905 ( Registry Identifier: ISRCTN )
15/SC/0259 ( Other Identifier: UK Health Research Authority )
CTU0028 ( Other Identifier: OCTRU )
First Submitted: May 23, 2017
First Posted: June 8, 2017
Last Update Posted: June 8, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Oxford:
Dupuytren
adalimumab
anti TNF
phase II clinical trial
randomized controlled trial
double-blind method

Additional relevant MeSH terms:
Dupuytren Contracture
Fibroma
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Contracture
Muscular Diseases
Musculoskeletal Diseases
Connective Tissue Diseases
Adalimumab
Anti-Inflammatory Agents
Antirheumatic Agents